Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Alrizomadlin by Ascentage Pharma Group International for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
Alrizomadlin is under clinical development by Ascentage Pharma Group International and currently in Phase II for Adenoid Cystic Carcinoma (ACC)....
Data Insights
Alrizomadlin by Ascentage Pharma Group International for Non-Hodgkin Lymphoma: Likelihood of Approval
Alrizomadlin is under clinical development by Ascentage Pharma Group International and currently in Phase II for Non-Hodgkin Lymphoma. According to...